Short Summary
Apple’s IPR resulted in the Board finding all six challenged claims of Omni MedSci’s ’299 patent unpatentable as obvious over a combination of prior‑art references covering wearable optical sensing.
Detailed Summary
In IPR2025-01253, Apple challenged claims 7 and 10–14 of Omni MedSci’s U.S. Patent No. 12,193,790 covering a wearable physiological measurement system. The Board instituted the review on all grounds raised and, after extensive analysis, concluded that the asserted claims were obvious under 35 U.S.C. §103. The decision relied on the combination of prior‑art references Lisogurski, Carlson, Mannheimer, and Park, finding that each limitation—including the pulse‑rate increase for signal‑to‑noise improvement—was taught or suggested. The Board accepted Petitioner’s evidence, expert testimony, and admissions by the Patent Owner, and ordered all challenged claims unpatentable.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in SAMSUNG ELECTRONICS CO., LTD. et al. vs OMNI MEDSCI, INC. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Taiwan Semiconductor Manufacturing Company Limited et al.vsMarlin Semiconductor Ltd. et al.
Court decision.
Godbersen-Smith Construction Company d/b/a GOMACO CorporationvsGuntert & Zimmerman Const. Div., Inc.
The PTAB held that all fifteen claims of GOMACO’s slipform paving machine patent are obvious over a combination of the Commander III manual, Rio’s rotary actuator, and other prior art, cancelling the entire patent.
SAMSUNG ELECTRONICS CO., LTD. et al.vsOMNI MEDSCI, INC.
The USPTO granted institution for IPR2025-01253 after determining the petitioner had a reasonable likelihood of prevailing on at least one challenged claim.
Apple Inc.vsTelcom Ventures LLC
Apple has filed an IPR petition seeking cancellation of all 16 claims of Telcom Ventures’ U.S. Patent 11,937,172, arguing the claims are obvious over a suite of prior‑art references covering NFC‑based mobile payments and biometric authentication.
Google LLCvsBrodTi Inc.
Google’s expert Mark Crovella files a reply declaration defending the ’898 patent against Dr. Myler’s claim constructions. He contends the terms are plain, the prior art discloses all claim elements, and the obviousness position should not change.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.